This article has been updated with additonal information from Courtagen Life Sciences and Medicinal Genomics.

NEW YORK (GenomeWeb) – Courtagen Life Sciences said today that it has closed its diagnostic neurology testing business. According to the firm's website, it no longer accepts patient samples. 

The company's wholly owned subsidiary, Medicinal Genomics Corporation (MGC), which provides cannabis genetics research and testing, will remain intact and Courtagen is taking on this name.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.